Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvoraleimab + Bev + nab-PC in Advanced Acral and Mucosal Melanoma
NCT07347444Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in acral lentiginous melanoma (ALM) and mucosal melanoma (MM), sponsored by Fudan University. Primary endpoint: Objective Response Rate up to 2 years. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT07347444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347444.